Afferent Pharmaceuticals Inc

Bruce G. McCarthy, M.D., chief executive officer
Dr. McCarthy joined Afferent in January 2010 as chief executive officer. He brings more than 20 years experience to Afferent, including roles of increasing responsibility at Pfizer, Inc., having served as vice president, neuroscience development where he led neuroscience drug development programs of new molecular entities and enhancements to marketed products. Prior to joining Pfizer, he held various roles at Abbott Laboratories from 1997 to 2004, including venture head, where he managed clinical development programs for early-stage neuroscience drug candidates, including ABT-594 (an NNR antagonist for pain). Most recently, as an industry consultant, Dr. McCarthy served as head of development and chief medical officer for several start-up companies developing treatments for neurological and psychiatric disorders. Dr. McCarthy received an M.B.A. from Kellogg School of Management, an M.D. from the Johns Hopkins University School of Medicine and a B.S. in biological sciences from Stanford University. He completed his residency in neurology at the University of California, San Francisco.
 
Anthony P. Ford, Ph.D., chief scientific officer
Dr. Ford is co-founder and chief scientific officer of Afferent. An accomplished pharmacologist and former vice president of research at Roche, Dr. Ford initiated and drove the P2X3 program at Roche for over a decade. Dr. Ford brings more than 20 years of research and development experience at Roche and Syntex to Afferent, having led the progression of several novel drug candidates into early clinical development, focused particularly in the areas of pain and genitourinary therapeutics.